1. Centers for Disease Control and Prevention. About Women and Heart Disease. Available at https://www.cdc.gov/heart-disease/about/women-and-heart-disease.html. Last accessed December 1, 2025.

2. Martin SS, Aday AW, Allen NB, et al. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151(8):e41-e660.

3. National Heart, Lung, and Blood Institute. What Is Coronary Heart Disease? Available at https://www.nhlbi.nih.gov/health/coronary-heart-disease. Last accessed December 1, 2025.

4. American Heart Association. 2025 Heart Disease and Stroke Statistics Update Fact Sheet. Available at https://professional.heart.org/en/science-news/-/media/42D9E9E6563743CCB48C44B1C8429D47.ashx. Last accessed December 1, 2025.

5. Khandelwal A, Bakir M, Bezaire M, et al. Managing ischemic cardiovascular disease in women: role of a women's heart center. Curr Atheroscl Rep. 2021;23(10):1-6.

6. American Heart Association. 2022 Heart Disease and Stroke Statistical Update Fact Sheet: Females and Cardiovascular Diseases. Available at https://professional.heart.org/-/media/PHD-Files-2/Science-News/2/2022-Heart-and-Stroke-Stat-Update/2022-Stat-Update-factsheet-Females-and-CVD.pdf. Last accessed December 1, 2025.

7. Framingham Heart Study. About the Framingham Heart Study. Available at https://www.framinghamheartstudy.org/fhs-about. Last accessed December 1, 2025.

8. Population Reference Bureau. Fact Sheet: Aging in the United States. Available at https://www.prb.org/resources/fact-sheet-aging-in-the-united-states. Last accessed December 1, 2025.

9. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) study: part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47(3 Suppl S):S21-S29.

10. Plank F, Beyer C, Friedrich G, Waildauer M, Feuchtner G. Sex differences in coronary artery plaque composition detected by coronary computed tomography: quantitative and qualitative analysis. Neth Heart J. 2019;27(5):272-280.

11. Zaid M, Sala L, Despins L, Heise D, Popescu M, Skubic M, Ahmad S, Emter CA, Huxley VH, Guidoboni G. Cardiovascular sex-differences: insights via physiology-based modeling and potential for noninvasive sensing via ballistocardiography. Front Cardiovasc Med. 2023;10:1215958.

12. Beale AL, Meyer P, Marwick TH, et al. Sex differences in cardiovascular pathophysiology: why women are overrepresented in heart failure with preserved ejection fraction. Circulation. 2018;138(2).

13. Kim HL. Differences in risk factors for coronary atherosclerosis according to sex. J Lipid Atheroscler. 2024;13(2):97-110.

14. Betai D, Ahmed AS, Saxena P, et al. Gender Disparities in cardiovascular disease and their management: a review. Cureus. 2024;16(5):e59663.

15. Mehta LS, Velarde GP, Lewey J, et al. Cardiovascular risk factors in women: the impact of race and ethnicity; a scientific statement from the American Heart Association. Circulation. 2023;147(19):1471-1487.

16. Adedinsewo DA, Pollak AW, Phillips SD, et al. Cardiovascular disease screening in women: leveraging artificial intelligence and digital tools. Circulation Research. 2022;130(4):673-690.

17. American Heart Association Go Red for Women Life's Essential 8 for Women. Available at https://www.goredforwomen.org/en/know-your-risk/lifes-essential-8-for-women. Last accessed December 1, 2025.

18. Centers for Disease Control and Prevention. Health Effects of Cigarettes: Cardiovascular Disease. Avialable at https://www.cdc.gov/tobacco/about/cigarettes-and-cardiovascular-disease.html. Last accessed December 1, 2025.

19. Sarna L, Bialous SA, Jun HJ, Wewers ME, Cooley ME, Feskanich D. Smoking trends in the Nurses' Health Study (1976–2003). Nurs Res. 2008;57(6):374-382.

20. U.S. Department of Health and Human Services. Smoking Cessation: A Report of the Surgeon General. Available at https://www.hhs.gov/sites/default/files/2020-cessation-sgr-full-report.pdf. Last accessed December 1, 2025.

21. American Lung Association. Women and Tobacco Use. Available at https://www.lung.org/quit-smoking/smoking-facts/impact-of-tobacco-use/women-and-tobacco-use. Last accessed December 1, 2025.

22. National Heart, Lung, and Blood Institute. What is High Blood Pressure? Available at https://www.nhlbi.nih.gov/health/high-blood-pressure. Last accessed December 1, 2025.

23. Jones, D, Ferdinand, K, Taler, S. et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC. 2025;86(18):1567–1678.

24. Rosendorff C, Lackland DT, Allison M, et al. AHA/ACC/ASH scientific statement: treatment of hypertension in patients with coronary artery disease: a scientific statement from the American heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015;65:1372-1407.

25. Chapman N, Ching SM, Konradi AO, et al. Arterial hypertension in women: state of the art and knowledge gaps. Hypertension. 2023;80(6):1140-1149.

26. U.S. Preventive Services Task Force. Screening for peripheral artery disease and CHD risk assessment with the ankle-brachial index: U.S. Preventive Services Task Force recommendation statement. JAMA. 2018;320(2):177-183.

27. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197-208.

28. Carroll MD, Fryar CD, Gwira JA, Iniguez M. Total and high-density lipoprotein cholesterol in adults: United States, August 2021–August 2023. NCHS Data Brief, no 515. Hyattsville, MD: National Center for Health Statistics. 2024.

29. 2018 Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.

30. American Heart Association. What Your Cholesterol Levels Mean. Available at https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/what-your-cholesterol-levels-mean. Last accessed December 1, 2025.

31. Centers for Disease Control and Prevention. High Cholesterol Facts. Available at https://www.cdc.gov/cholesterol/data-research/facts-stats. Last accessed December 1, 2025.

32. Mehta LS, Beckie TM, DeVon HA, et al. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 2016;133(9):916-947.

33. National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation. National Diabetes Statistics Report, 2024. Available at https://www.cdc.gov/diabetes/php/data-research/index.html. Last accessed December 1, 2025.

34. Centers for Disease Control and Prevention National Center for Health Statistics. National Vital Statistics System, Mortality 2018-2023 on CDC WONDER Online Database. Availabe at http://wonder.cdc.gov/ucd-icd10-expanded.html. Last accessed December 1, 2025.

35. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542-1551.

36. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. NCHS Data Brief, No 508. Available at https://www.cdc.gov/nchs/data/databriefs/db508.pdf. Last accessed December 1, 2025.

37. Centers for Disease Control and Prevention. Adult Obesity Prevalence Maps. Available at https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html. Last accessed December 1, 2025.

38. Zhang B, Shi H, Cai W, Yang B, Xiu W. Metabolic syndrome in children and adolescents: definitions, epidemiology, pathophysiology, interventions, and challenges. Front Endocrinol. 2025;16:1512642.

39. American Heart Association. Metabolic Syndrome. Available at https://www.heart.org/en/health-topics/metabolic-syndrome. Last accessed December 1, 2025.

40. Hyde ET, Whitfield GP, Omura JD, Fulton JE, Carlson SA. Trends in meeting the physical activity guidelines: muscle-strengthening alone and combined with aerobic activity, United States, 1998–2018. J Phys Act Health. 2021;18(Suppl 1):S37-S44.

41. Centers for Disease Control and Prevention. About Sleep and Your Heart Health. Available at https://www.cdc.gov/heart-disease/about/sleep-and-heart-health.html. Last accessed December 1, 2025.

42. Jaspan VN, Greenberg GS, Parihar S. et al. The role of sleep in cardiovascular disease. Curr Atheroscler Rep 2024;26:249–262.

43. Campos-Rodriguez F, Martinez-Garcia MA, Reyes-Nuñez N, et al. Role of sleep apnea and continuous positive airway pressure therapy in the incidence of stroke or coronary heart disease in women. A J Resp Crit Care Med. 2014;189(12):1544-1550.

44. Janssen I, Powell LH, Everson-Rose SA, et al. Psychosocial well-being and progression of coronary artery calcification in midlife women. J Am Heart Assoc. 2022;11(5):e023937.

45. Cené CW, Leng XI, Faraz K, et al. Social isolation and incident heart failure hospitalization in older women: Women's Health Initiative Study Findings. J Am Heart Assoc. 2022;11(5):e022907.

46. National Heart, Lung, and Blood Institute. Coronary Heart Disease: Women and Heart Disease. Available at https://www.nhlbi.nih.gov/health/coronary-heart-disease/women. Last accessed December 1, 2025.

47. Anderer S. Some hormonal birth control tied to greater risk of heart attack and stroke. JAMA. 2025;333(16):1385.

48. American Heart Association Go Red for Women. Birth Control and Heart Disease in Women. Available at https://www.goredforwomen.org/en/know-your-risk/pregnancy-and-maternal-health/pregnancy-and-risk-factors/birth-control-and-heart-disease. Last accessed December 1, 2025.

49. Vetter C, Devore EE, Wegrzyn LR, et al. Association between rotating night shift work and risk of coronary heart disease among women. JAMA. 2016;315(16):1726-1734.

50. Taber's Online Medical Dictionary. Available at https://www.tabers.com/tabersonline. Last accessed December 1, 2025.

51. Peng HY, Man CF, Xu J, Fan Y. Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies. J Zhejiang Univ Sci B. 2015;16(1):78-86.

52. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. ATVB. 2021;42(1):e48-e60.

53. Ridker PM. C-reactive protein. A simple test to help predict risk of heart attack and stroke. Circulation. 2003;108:e81-e85.

54. Amezcua-Castillo E, González-Pacheco H, Sáenz-San Martín A, et al. C-Reactive protein: the quintessential marker of systemic inflammation in coronary artery disease-advancing toward precision medicine. Biomedicines. 2023;11(9):2444.

55. Sharma K, Gulati M. Coronary artery disease in women: a 2013 update. Global Heart. 2013;8(2):105-112.

56. Wenger NK. The Reynolds Risk Score: improved accuracy for cardiovascular risk prediction in women? Nat Clin Pract Cardiovasc Med. 2007;4:366-367.

57. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of CHD in women. N Engl J Med. 2000;342(12):836-843.

58. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER): can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006;97(2A):33A-41A.

59. O'Keefe JH, Carter MD, Lavie CJ, Bell DS. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin). Postgrad Med. 2009;121(3):113-118.

60. Joanna Briggs Institute. Nurse-led cardiac clinics for adults with CHD. Best Practice. 2005;9(1):1-6.

61. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and CHD: implications for risk assessment. J Am Coll Cardiol. 2004;44(10):1945-1956.

62. Liccardo D, Cannavo A, Spagnuolo G, et al. Periodontal disease: a risk factor for diabetes and CHD. Int J Mol Sci. 2019;20(6).

63. Wu T, Trevisan M, Genco RJ, Falkner KL, Dorn JP, Sempos CT. Examination of the relation between periodontal health status and cardiovascular risk factors: serum total and high-density lipoprotein cholesterol, C-reactive protein, and plasma fibrinogen. Am J Epidemiol. 2000;151(3):273-282.

64. Koenig W. Fibrin(ogen) in CHD: an update. Thromb Haemost. 2003;89(4):601-609.

65. Fibrinogen Studies Collaboration, Danesh J, Lewington S, et al. Plasma fibrinogen level and the risk of major CHDs and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799-1809.

66. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291(2):228-238.

67. Redford C, Vaidya B. Subclinical hypothyroidism: should we treat? Post Reprod Health. 2017;23(2):55-62.

68. Farrell MA, Hayashi T, Loo RK, et al. Clinic-based nutrition and lifestyle counseling for Hispanic women delivered by community health workers: design of the California WISEWOMAN study. J Womens Health (Larchmt). 2009;18(5):733-739.

69. Mehta LS, Watson KE, Barac A, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137(8):e30-e66.

70. American Heart Association. The Slowly Evolving Truth about Heart Disease and Women. Available at https://www.heart.org/en/news/2024/02/09/the-slowly-evolving-truth-about-heart-disease-and-women. Last accessed December 1, 2025.

71. American Heart Association. Go Red for Women. Available at https://www.goredforwomen.org. Last accessed December 1, 2025.

72. Brittle C, Bird CE. Literature Review on Effective Sex- and Gender-Based Systems/Models of Care. Arlington, VA: U.S. Office on Women's Health; 2007.

73. Centers for Disease Control and Prevention. Heart Disease Facts. Available at https://www.cdc.gov/heartdisease/facts.htm. Last accessed December 1, 2025.

74. American Heart Association. About Heart Disease in Women. Available at https://www.goredforwomen.org/home/about-heart-disease-in-women. Last accessed December 1, 2025.

75. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of CHD in women—2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-1262.

76. Moore L. Shifting Behavior with the "Stages of Change." Available at https://psychcentral.com/lib/stages-of-change. Last accessed December 1, 2025.

77. Mons U, Muezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ. 2015;350:h1551.

78. Perkins KA, Marcus MD, Levine MD, et al. Cognitive-behavioral therapy to reduce weight concerns improves smoking cessation outcome in weight-concerned women. J Consult Clin Psychol. 2001;69(4):604-613.

79. Centers for Disease Control and Prevention. BMI Frequently Asked Questions. Available at https://www.cdc.gov/bmi/faq. Last accessed December 1, 2025.

80. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and CHD in women. JAMA. 1998;280(21):1843-1848.

81. Zong G, Li Y, Wanders AJ, Alssema M, et al. Intake of individual saturated fatty acids and risk of coronary heart disease in U.S. men and women: two prospective longitudinal cohort studies. BMJ. 2016;23:355.

82. Sun Y, Liu B, Snetselaar LG, et al. Association of major dietary protein sources with all-cause and cause-specific mortality: prospective cohort study. J Am Heart Assoc. 2021;10(5):e015553.

83. U.S. Department of Agriculture. My Plate. Available at https://www.myplate.gov. Last accessed December 1, 2025.

84. Mayo Clinic. Nutrition and Health Eating: DASH Diet: Healthy Eating to Lower Your Blood Pressure. Available at https://www.mayoclinic.org/healthy-lifestyle/nutrition-and-healthy-eating/in-depth/dash-diet/art-20048456. Last accessed December 1, 2025.

85. Jones P, Lucock M, Scarlett CJ, Veysey M, Beckett EL. Folate and inflammation: links between folate and features of inflammatory conditions. J Nutr Intermed Metab. 2019;18:100104.

86. American Heart Association. Is Drinking Alcohol Part of a Healthy Lifestyle? Available at https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/nutrition-basics/alcohol-and-heart-health. Last accessed December 1, 2025.

87. Hozumi T, Sugioka K, Shimada K, et al. Beneficial effect of short term intake of red wine polyphenols on coronary microcirculation in patients with coronary artery disease. Heart. 2006;92(5):681-682.

88. King SJ, Yuthok TYW, Bacong AM, et al. Heart disease mortality in the United States, 1970 to 2022. J Am Heart Assoc. 2025;14(13): e038644.

89. U.S. Census Bureau. Population Projections. Available at https://www.census.gov/programs-surveys/popproj.html. Last accessed December 1, 2025.

90. Agency for Healthcare Research and Quality. CHD and Other Chronic Conditions in Women: Recent Findings (Program Brief). Available at https://www.ahrq.gov/sites/default/files/publications/files/womheart.pdf. Last accessed December 1, 2025.

91. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-2853.

92. US Preventive Services Task Force. Final Recommendation Statement: CHD Risk: Risk Assessment with Nontraditional Risk Factors. Available at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/cardiovascular-disease-screening-using-nontraditional-risk-assessment. Last accessed December 1, 2025.

93. American Heart Association. Prenatal Supplement May Increase Blood Pressure at High Doses. Available at https://www.heart.org/en/news/2020/05/11/prenatal-supplement-may-increase-blood-pressure-at-high-doses. Last accessed December 1, 2025.

94. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R Sr., O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008;1(2):92-97.

95. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for CHD: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151(7):483-495.

96. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of CHD events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38(1):217-231.

97. U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans. Available at https://health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_edition.pdf. Last accessed December 1, 2025.

98. Boldo A, White WB. Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies. Endocrinol Metab Clin North Am. 2011;40(2):419-432.

99. Womenshealth.gov. Birth Control Methods. Available at https://www.womenshealth.gov/a-z-topics/birth-control-methods. Last accessed December 1, 2025.

100. American Heart Association. The American Heart Association's Diet and Lifestyle Recommendations. Available at https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/nutrition-basics/aha-diet-and-lifestyle-recommendations. Last accessed December 1, 2025.

101. Flavell CM. Women and CHD. Prog Cardiovasc Nurs. 1994;9(4):18-27.

102. Hennekens CH, Buring JE, Peto R. Antioxidant vitamins-benefits not yet proved. N Engl J Med. 1994;330(15):1080-1081.

103. Leopold JA. Antioxidants and coronary artery disease: from pathophysiology to preventive therapy. Coron Artery Dis. 2015;26(2):176-183.

104. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL, for the Nutrition Committee of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Antioxidant vitamin supplements and CHD. Circulation. 2004;110(5):637-641.

105. Lewis JR, Radavelli-Bagatini S, Rejnmark L, et al. The effects of calcium supplementation on verified coronary heart disease hospitalization and death in postmenopausal women: a collaborative meta-analysis of randomized controlled trials. Journal Bone and Mineral Research. 2015;30(1):165-175.

106. Manson JE, Willett WC, Stampfer MJ, et al. A prospective study of aspirin use and primary prevention of CHD in women. JAMA. 1991;266(4):521-527.

107. U.S. Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. JAMA. 2022;327(16):1577-1584.

108. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329-1339.

109. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of CHD in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7): 605-613.

110. Hsai J, Langer RD, Manson JE, et al. Conjugated equine estrogens and CHD: the Women's Health Initiative. Arch Intern Med. 2006;166(3):357-365.

111. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.

112. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343(8):522-529.

113. King KB, Rowe MA, Zerwic JJ. Concerns and risk factor modification in women during the year after coronary artery surgery. Nurs Res. 2000;49(3):167-172.

114. U.S. Preventive Services Task Force. Hormone therapy for the primary prevention of chronic conditions in postmenopausal persons: U.S. Preventive Services Task Force recommendation statement. JAMA. 2022;328(17):1740-1746.

115. Institute for Clinical Systems Improvement. Menopause and Hormone Therapy: Collaborative Decision-Making and Management. Bloomington, MN: Institute for Clinical Systems Improvement; 2008.

116. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing CHD in post-menopausal women. Cochrane Database Syst Rev. 2015;(3):CD002229.

117. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC. 2021;78(22):e187-e285.

118. American Heart Association. Radionuclide Ventriculography or Radionuclide Angiography (MUGA Scan). Available at https://www.heart.org/en/health-topics/heart-attack/diagnosing-a-heart-attack/radionuclide-ventriculography-or-radionuclide-angiography-muga-scan. Last accessed December 1, 2025.

119. Taylor P, Becker RC. Noninvasive diagnosis of CHD in women. Cardiology. 1990;77(Suppl 2):91-98.

120. Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation. 2005;111(5):682-696.

121. Gökçe M, Karahan B, Yilmaz R, Orem C, Erdöl C, Ozdemir S. Long term effects of hormone replacement therapy on heart rate variability, QT interval, QT dispersion and frequencies of arrhythmia. Int J Cardiol. 2005;99(3):373-379.

122. Sedlak T, Shufelt C, Iribarren C, Merz CN. Sex hormones and the QT interval: a review. J Womens Health (Larchmt). 2012;21(9):933-941.

123. Mieres JH, Gulati M, Merz NB, et al. Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association. Circulation. 2014;139(4):350-379.

124. Marwick TH. Stress echocardiography. Heart. 2003;89:113-118.

125. Greulich S, Bruder O, Parker M, et al. Comparison of exercise electrocardiography and stress perfusion CMR for the detection of coronary artery disease in women. J Cardiovasc Magn Reson. 2012;14:36.

126. Akinpelu D. Pharmacologic Stress Testing. Available at https://emedicine.medscape.com/article/1827166-overview. Last accessed December 1, 2025.

127. LexiDrug. Available at https://online.lexi.com. Last accessed December 1, 2025.

128. U.S. Food and Drug Administration. Archive: Safety Alert: Lexiscan (Regadenoson) and Adenoscan (Adenosine): Drug Safety Communication—Rare but Serious Risk of Heart Attack and Death. Available at https://wayback.archive-it.org/7993/20170406124140/https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm375981.htm. Last accessed December 1, 2025.

129. U.S. Food and Drug Administration. FDA Warns of Rare but Serious Risk of Heart Attack and Death with Cardiac Nuclear Stress Test Drugs Lexiscan (Regadenoson) and Adenoscan (Adenosine). Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-rare-serious-risk-heart-attack-and-death-cardiac-nuclear-stress-test-drugs-lexiscan. Last accessed December 1, 2025.

130. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr. 2011;24(3):229-267.

131. Arbab-Zadeh A. Stress testing and non-invasive coronary angiography in patients with suspected coronary artery disease: time for a new paradigm. Heart Int. 2012;7:32.

132. Boden WE. Is myocardial perfusion imaging an important predictor of mortality in women and if so, is this likely cost effective? J Am Coll Cardiol Img. 2011;4(8):889-893.

133. Rathore SS, Chen J, Wang Y, Radford MJ, Vaccarino V, Krumholz HM. Sex differences in cardiac catheterization: the role of physician gender. JAMA. 2001;286(22):2849-2856.

134. Gold LD, Krumholz HM. Gender differences in treatment of heart failure and acute myocardial infarction: a question of quality or epidemiology? Cardiol Rev. 2006;14(4):180-186.

135. Kaczmarek RG, Liu CH, Gross TP. Medical device surveillance: gender differences in pulmonary artery rupture after pulmonary artery catheterization. J Womens Health (Larchmt). 2003;12(9):931-935.

136. King KM, Ghali WA, Faris PD, et al. Sex differences in outcomes after cardiac catheterization: effect modification by treatment strategy and time. JAMA. 2004;291(10):1220-1225.

137. Jacobs AK. Women, ischemic heart disease, revascularization, and the gender gap. What are we missing? J Am Coll Cardiol. 2006;47(Suppl S):S63-S65.

138. Fabreau GE, Leung AA, Southern DA, et al. Sex, socioeconomic status, access to cardiac catheterization, and outcomes for acute coronary syndromes in the context of universal healthcare coverage. Circ Cardiovasc Qual Outcomes. 2014;7(4):540-549.

139. American Heart Association. Heart Attack Symptoms in Women. Available at https://www.heart.org/en/health-topics/heart-attack/warning-signs-of-a-heart-attack/heart-attack-symptoms-in-women. Last accessed December 1, 2025.

140. Hemingway H, Langenberg C, Damant J, Frost C, Pyorala K, Barrett-Connor E. Prevalence of angina in women versus men: a systematic review and meta-analysis of international variations across 31 countries. Circulation. 2008;117(12):1526-1536.

141. American Heart Association. Unstable Angina. Available at https://www.heart.org/en/health-topics/heart-attack/angina-chest-pain/unstable-angina. Last accessed December 1, 2025.

142. Wang SS. Coronary Artery Vasospasm. Available at https://emedicine.medscape.com/article/153943-overview. Last accessed December 1, 2025.

143. Devabhaktuni SR. Cardiac Syndrome X. Available at https://emedicine.medscape.com/article/1967073-overview. Last accessed December 1, 2025.

144. National Institutes of Health. WISE Study of Women and Heart Disease Yields Important Findings on Frequently Undiagnosed Coronary Syndrome. Available at https://www.nih.gov/news-events/news-releases/wise-study-women-heart-disease-yields-important-findings-frequently-undiagnosed-coronary-syndrome. Last accessed December 1, 2025.

145. American Heart Association. Microvascular Angina. Available at https://www.heart.org/en/health-topics/heart-attack/angina-chest-pain/microvascular-angina. Last accessed December 1, 2025.

146. Cannon RO III. Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms. J Am Coll Cardiol. 2009;54(10):877-885.

147. Rosenfeld AG. Treatment-seeking delay among women with acute myocardial infarction: decision trajectories and their predictors. Nurs Res. 2004;53(4):225-236.

148. Khraim FM, Carey MG. Predictors of pre-hospital delay among patients with acute myocardial infarction. Patient Educ Couns. 2009;75(2):155-161.

149. de Torbal A, Boersma E, Kors JA, et al. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. Eur Heart J. 2006;27:729-736.

150. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM, for the National Registry of Myocardial Infarction 2 Participants. Sex-based differences in early mortality after myocardial infarction. N Engl J Med. 1999;341(4):217-225.

151. Vaccarino V, Parsons L, Peterson ED, Rogers WJ, Kiefe CI, Canto J. Sex differences in mortality after acute myocardial infarction: changes from 1994 to 2006. Arch Intern Med. 2009;169(19):1767-1774.

152. Packard B. Clinical aspects of CHD in women. In: Wenger NK, Hellerstein HK (eds). Rehabilitation of the Coronary Patient. 3rd ed. New York, NY: Churchill Livingstone; 1991.

153. Cochrane BL. Acute myocardial infarction in women. Crit Care Nurs Clin North Am. 1992;4(2):279-289.

154. Wingate S. Women and CHD: implications for the critical care setting. Focus Crit Care. 1991;18(3):212-214, 216-218, 220.

155. Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation, and outcome in patients with acute coronary syndromes: global use of strategies to open occluded coronary arteries in acute coronary syndromes llb investigators. N Engl J Med. 1999;341(4):226-232.

156. Tillmanns H, Waas W, Voss R, et al. Gender differences in the outcome of cardiac interventions. Herz. 2005;30(5):375-389.

157. Zimmermann S, Ruthrof S, Nowak K, et al. Short-term prognosis of contemporary interventional therapy of ST-elevation myocardial infarction: does gender matter? Clin Res Cardiol. 2009;98(11):709-715.

158. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.

159. Sarafoff N, Byrne RA, Sibbing D. Clinical use of clopidogrel. Curr Pharm Des. 2012;18(33):5224-5239.

160. Martischnig AM, Mehili J, Pollak J, et al. Impact of dabigatran versus phenprocoumon on ADP induced platelet aggregation in patients with atrial fibrillation with or without concomitant clopidogrel therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials). Biomed Res Int. 2015;798486.

161. Olivier CB, Diehl P, Schnabel K, et al. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry. Thromb Haemost. 2014;111(2):266-272.

162. Olivier CB, Schnabel K, Weber S, et al. Platelet reactivity after administration of third generation P2Y12 antagonists does not depend on body weight in contrast to clopidogrel. J Thromb Thrombolysis. 2016;42(1):84-89.

163. Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO II-B) Angioplasty Substudy. Am Heart J. 2004;147(1):133-139.

164. Mallik S, Vaccarino V. Outcomes of thrombolytic therapy for acute myocardial infarction in women. Prog Cardiovasc Dis. 2004;47(1):58-71.

165. Ostadal P, Ostadal B. Women and the management of acute coronary syndrome. Can J Physiol Pharmacol. 2012;90(9):1151-1159.

166. Spaander FH, Zinkstok SM, Baharoglu IM, et al. Sex differences and functional outcome after intravenous thrombolysis. Stroke. 2017;48:699-703.

167. Bots SH, Groepenhoff F, Eikendal AL, et al. Adverse drug reactions to guideline-recommended heart failure drugs in women: a systematic review of the literature. JACC: Heart Failure. 2019;7(3):258-266.

168. Tamargo J, Rosano G, Walther T, et al. Gender differences in the effects of cardiovascular drugs. European Heart Journal. 2017;3(3):163-182.

169. Movahed MR, Ramaraj R, Jamal MM, Hashemzadeh M. Nationwide trends in the utilization of multivessel percutaneous coronary intervention (MVPCI) in the United States across different gender and ethnicities. J Interv Cardiol. 2009;22(3):247-251.

170. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-e651.

171. Singh M, Rihal CS, Gersh BJ, et al. Mortality differences between men and women after percutaneous coronary interventions: a 25-year, single-center experience. J Am Coll Cardiol. 2008;51(24):2313-2320.

172. Smith SC, Feldman TE, Hirshfield JW, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous intervention. J Am Coll Cardiol. 2006;47(1):e1-e121.

173. Smith SC Jr, Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines): executive summary. Circulation. 2001;103:3019-3041.

174. Naito R, Miyauchi K, Konishi H, et al. Gender difference in long-term clinical outcomes following percutaneous coronary intervention during 1984–2008. Atherosclerosis. 2016;247:105-110.

175. De Luca G, Suryapranata H, Dambrink JH, et al. Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle Myocardial Infarction Study. Am Heart J. 2004;148(5):852-856.

176. Pancholy SB, Shantha GP, Patel T, Cheskin LJ. Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis. JAMA Intern Med. 2014;174(11):1822-1830.

177. Karthik S, Fabri BM. Left internal mammary artery usage in coronary artery bypass grafting: a measure of quality control. Ann R Coll Surg Engl. 2006;88(4):367-369.

178. Harskamp RE, Alexander JH, Ferguson B Jr, et al. Frequency and predictors of internal mammary artery graft failure and subsequent clinical outcomes: insights from the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. Circulation. 2016;133:131-138.

179. Vaccarino V, Koch CG. Long-term benefits of coronary bypass surgery: are the gains for women less than for men? J Thorac Cardiovasc Surg. 2003;126(6):1707-1711.

180. Vaccarino V, Abramson JL, Veledar E, Weintraub WS. Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation. 2002;105(10):1176-1181.

181. Gaudino M, Angelini GD, Antoniades C, et al. Off-pump coronary artery bypass grafting: 30 years of debate. J Am Heart Assoc. 2018;7(16):e009934.

182. Lamy A, Devereaux PJ, Prabhakaran D, et al. Five-year outcomes after off-pump or on-pump coronary-artery bypass grafting. N Engl J Med. 2016;375(24):2359-2368.

183. Shroyer AL, Hattler B, Wagner TH, et al. Five-year outcomes after on-pump and off-pump coronary-artery bypass. N Engl J Med. 2017;377(7):623-632.

184. Di Mauro M, Gagliardi M, Iaco AL, et al. Does off-pump coronary surgery reduce postoperative acute renal failure? The importance of preoperative renal function. Ann Thorac Surg. 2007;84(5):1496-1502.

185. Kirmani BH, Holmes MV, Muir AD. Long-term survival and freedom from reintervention after off-pump coronary artery bypass grafting. Circulation. 2016;134(17):1209-1220.

186. Moore SM. A comparison of women's and men's symptoms during home recovery after coronary artery bypass surgery. Heart Lung. 1995;24(6):495-501.

187. King KM, Gortner SR. Women's short-term recovery from cardiac surgery. Prog Cardiovasc Nurs. 1996;11(2):5-15.

188. Edwards ML, Albert NM, Wang C, Apperson-Hansen C. 1993–2003 gender differences in coronary artery revascularization: has anything changed? J Cardiovasc Nurs. 2005;20(6):461-467.

189. Piña IL, Zheng Q, She L, et al. Sex difference in patients with ischemic heart failure undergoing surgical revascularization: results from the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2018;137(8):771-780.

190. Smith JR, Thomas RJ, Bonikowske AR, et al. Sex differences in cardiac rehabilitation outcomes. Circulation Research. 2022;130(4): 552-565.

191. De Vos C, Li X, Van Vlaenderen I, et al. Participating or not in a cardiac rehabilitation programme: factors influencing a patient's decision. Euro J Preventive Cardiol. 2013;20(2):341-348.

192. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC, MERIT-HF Study Group. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002;105(13):1585-1591.

193. Grace SL, Gravely-Witte S, Brual J, et al. Contribution of patient and physician factors to cardiac rehabilitation referral: a prospective multilevel study. Nat Clin Pract Cardiovasc Med. 2008;5(10):653-662.

194. Moradi B, Maleki M, Esmaeilzadeh M, Abkenar HB. Physician-related factors affecting cardiac rehabilitation referral. J Tehran Heart Cent. 2011;6(4):187-192.

195. Halm M, Penque S, Doll N, Beahrs M. Women and cardiac rehabilitation: referral and compliance patterns. J Cardiovasc Nurs. 1999;13(3):83-92.

196. Colbert JD, Martin BJ, Haykowsky MJ, et al. Cardiac rehabilitation referral, attendance and mortality in women. Eur J Prev Cardiol. 2015;22(8):979-986.

197. Shanmugasegaram S, Oh P, Reid RD, McCumber T, Grace SL. Cardiac rehabilitation barriers by rurality and socioeconomic status: a cross-sectional study. Int J Equity Health. 2013;12(1):72.

198. Sanderson BK, Shewchuk RM, Bittner V. Cardiac rehabilitation and women: what keeps them away? J Cardiopulm Rehabil Prev. 2010;30(1):12-21.

199. Cannistra LB, Balady GJ, O'Malley CJ, Weiner DA, Ryan TJ. Comparison of the clinical profile and outcome of women and men in cardiac rehabilitation. Am J Cardiol. 1992;69(16):1274-1279.

200. Beswick AD, Rees K, West RR, et al. Improving uptake and adherence in cardiac rehabilitation: literature review. J Adv Nurs. 2005;49(5):538-555.

201. Chyun D. Nursing management of CHD in women: using research findings. Crit Care Nurse. 1997;17(2):10, 12, 14.

202. Gravely S, Anand SS, Stewart DE, Grace SL, CRCARE Investigators. Effect of referral strategies on access to cardiac rehabilitation among women. Eur J Prev Cardiol. 2014;21(8):1018-1025.

203. Santiago de Arujo PC, Chaves GS, Davies P, Taylor RS, Grace SL. Interventions to promote patient utilization of cardiac rehabilitation. Cochrane Database Syst Rev. 2019;2:CD007131.

204. Azad NA, Bouchard K, Mayhew A, Carter M, Molnar FJ. Safety and predictors of adherence of a new rehabilitation program for older women with congestive heart failure. J Geriatr Cardiol. 2012;9(3):243-246.

205. Shabani R, Gaeini AA, Nikoo MR, Nikbackt H, Sadegifar M. Effect of cardiac rehabilitation program on exercise capacity in women undergoing coronary artery bypass graft in Hamadan-iran. Int J Prev Med. 2010;1(4):247-251.

206. Ghashghaei FE, Sadeghi M, Marandi SM, Ghashghaei SE. Exercise-based cardiac rehabilitation improves hemodynamic responses after coronary artery bypass graft surgery. ARYA Atheroscler. 2012;7(4):151-156.

207. Kim C, Youn JE, Choi HE. The effect of a self-exercise program in cardiac rehabilitation for patients with coronary artery disease. Ann Rehabil Med. 2011;35(3):381-387.

208. European Society of Cardiology. Heart Attack Patients Return to Work Later and Retire Earlier if Treatment is Delayed. Available at https://www.escardio.org/The-ESC/Press-Office/Press-releases/Heart-attack-patients-return-to-work-later-and-retire-earlier-if-treatment-is-de. Last accessed December 1, 2025.

209. Halm MA, Alpen MA. Support groups: an annotated bibliography for critical care nurses. Crit Care Nurse. 1994;14(3):118-128.

210. American Heart Association. Cardiovascular Disease: Women's No. 1 Health Threat. Available at https://www.heart.org/-/media/files/about-us/policy-research/fact-sheets/access-to-care/cvd-womens-no-1-health-threat-fact-sheet.pdf. Last accessed December 1, 2025.

211. National Institute of Nursing Research. Matters of the Heart: A Research Journey Uncovering Signs of Heart Disease in Women. Available at https://www.ninr.nih.gov/newsandevents/events/2019-ninr-directors-lecture-dr-jean-c-mcsweeney-presents-matters-heart. Last accessed December 1, 2025.

212. Pereira de Melo R, Venicios de Oliveira Lopes M, Leite de Araujo T, de Fatima da Silva L, Aline Arrais Sampaio Santos F, Moorhead S. Risk for decreased cardiac output: validation of a proposal for nursing diagnosis. Nurs Crit Care. 2011;16(6):287-294.

213. Heidenreich PA, Bozkurt BB, Allen LA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032.

214. Hsich EM, Piña, IL. Heart failure in women: a need for prospective data. J Am Coll Cardiol. 2009;54(6):491-498.

215. National Heart, Lung, and Blood Institute. What is Angina? Available at https://www.nhlbi.nih.gov/health-topics/angina. Last accessed December 1, 2025.

216. Alaeddini J. Angina Pectoris Treatment and Management. Available at https://emedicine.medscape.com/article/150215-treatment. Last accessed December 1, 2025.

217. American Heart Association. Angina in Women can be Different than Men. Available at https://www.heart.org/en/health-topics/heart-attack/angina-chest-pain/angina-in-women-can-be-different-than-men. Last accessed December 1, 2025.

218. Lloyd GW, Patel NR, McGing E, Cooper AF, Brennand-Roper D, Jackson G. Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease? Heart. 2000;84(2):189-192.

219. Kawano H, Motoyama T, Ohgushi M, Kugiyama K, Ogawa H, Yasue H. Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina. Ann Intern Med. 2001;135(11):977-981.

220. Luca MC, Liuni A, Harvey P, Mak S, Parker JD. Effects of estradiol on measurements of conduit artery endothelial function after ischemia and reperfusion in premenopausal women. Can J Physiol Pharmacol. 2016;94(12):1304-1308.

221. National Heart, Lung, and Blood Institute. The Heart Truth. Available at https://www.nhlbi.nih.gov/health-topics/education-and-awareness/heart-truth. Last accessed December 1, 2025.

222. han Y, Chen J, Zhou S, Wen G. Nursing Interventions and Care Strategies for Patients with Coronary Heart Disease: A Comprehensive Review. Galen Med J. 2023;12:e2994.

223. Centers for Disease Control and Prevention. Health Literacy. Available at https://www.cdc.gov/health-literacy. Last accessed December 1, 2025.

224. U.S. Department of Health and Human Services. Guidelines for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs. Available at https://www.fda.gov/media/75648/download. Last accessed December 1, 2025.

225. Angell M. Caring for women's health: what is the problem? N Engl J Med. 1993;329(4):271-272.

226. Gendered Innovations in Science, Health and Medicine, Engineering, and Environment. Heart Disease in Women: Formulating Research Questions. Available at http://genderedinnovations.stanford.edu/case-studies/heart.html#tabs-1. Last accessed December 1, 2025.

227. National Institutes of Health. Inclusion of Women and Members of Racial and/or Ethnic Minority Groups in Clinical Research, Amended. Available at https://grants.nih.gov/policy-and-compliance/policy-topics/inclusion/women-and-minorities. Last accessed December 1, 2025.

228. National Institutes of Health. Office of Research on Women's Health. Available at https://orwh.od.nih.gov. Last accessed December 1, 2025.

229. National Heart, Lung, and Blood Institute. Women's Health Initiative. Available at https://www.nhlbi.nih.gov/science/womens-health-initiative-whi. Last accessed December 1, 2025.

230. Maclaran K, Stevenson JC. Primary prevention of CHD with HRT. Women's Health. 2012;8(1):63-74.

231. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368.

232. U.S. Food and Drug Administration. Archive: Drugs. Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women. Available at https://wayback.archive-it.org/7993/20170722143601/https://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm. Last accessed December 1, 2025.

233. Maserejian NN, Lutfey KE, McKinlay JB. Do physicians attend to base rates? Prevalence data and statistical discrimination in the diagnosis of CHD. Health Serv Res. 2009;44(6):1933-1949.

234. Office of Research on Women's Health. NIH-Wide Strategic Plan for the Research on the Help of Women. Available at https://orwh.od.nih.gov/sites/orwh/files/docs/ORWH_NIH-Wide%20Strategic%20Plan_FY2024-2028-508C.pdf. Last accessed December 1, 2025.

235. Office of Research on Women's Health. Advancing Novel Science in Women's Health Research. Available at https://www.nlm.nih.gov/ep/answhr.html. Last accessed December 1, 2025.

236. Moroni F, Beneduce A, Giustino G, et al. Sex differences in outcomes after percutaneous coronary intervention or coronary artery bypass graft for left main disease: from the DELTA Registries. J Am Heart Assoc. 2022;11(5):e022320.